Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma

Cancer

Volumn 86, Issue 7, 1999, Pages 1307-1313

  Sato, Shinya ^a   Kigawa, Junzo ^a   Minagawa, Yukihisa ^a   Okada, Makoto ^a   Shimada, Muneaki ^a   Takahashi, Masakuni ^a   Kamazawa, Shunji ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2; Chemotherapy; Ovarian carcinoma; P53

Indexed keywords

CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0033214798     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1307::AID-CNCR28>3.0.CO;2-F     Document Type: Article

References (25)

1. Muggia FM. Cisplatin update. Semin Oncol 1991;8:1-4.
2. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993;72:804-8.
3. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993;74:777-9.
4. Kellen JA. Molecular interrelationships in multidrug resistance. Anticancer res 1994;14:433-5.
5. Lu S, Man S, Bani MR, Adachi D, Hawley RG, Kerbel RS, et al. Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. Cancer Res 1995;55:1139-45.
6. Kastan MB, Canman CE, Leonard CI. p53 cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
7. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
8. Okada M, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, et al. Alterations of the p53 gene and p53 protein expression in epithelial ovarian cancer before and after chemotherapy. Int J Clin Oncol 1998;3:240-6.
9. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
10. Deb S, Jackson CT, Subler MA, Martin DW. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 1992;66:6164-70.
11. Russmann H, Schmidt H, Caprioli A, Krach H. Highly conserved B-subunit genes of Shiga-like toxin II variants found in escherichia coli O157 strains. Microbiology 1994;118:335-40.
12. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-28.
13. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
14. Wang XW, Yeh H, Schaeffer L, Roy R, Monocollin V, Egly JM, et al. p53 modulation of TFIIH-associated nucleoide excision repair activity. Nat Genet 1995;10:188-95.
15. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, et al. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 1998;34:1802-6.
16. Landesman Y, Bringold F, Kimchi A. p53 undergoes eitopic changes in vitro by sodium-vanadate. Oncogene 1994; 9:1241-5.
17. Kraiss S, Spiess S, Reihsaus E, Montenarh M. Correlation of metabolic stability and altered quanternacy structure of oncoprotein p53 with cell transformation. Exp Cell Res 1991; 192:157-64.
18. Fritsche M, Haessler C, Brandner G. Nuclear accumulation of p53: an indicator of chromatin injury ? [abstract]. J Cancer Res Clin Oncol 1991;117:30.
19. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA, et al. Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Arch 1995;426:339-44.
20. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78(8):1762-74.
21. El Habashi AH, Freeman SM, El Morsi B, Morris GF, Marrogi AJ. p53 and PCNA coexpression of 81 pleural and peritoneal effusion specimens: an immunohistochemical study. Pathol Res Pract 1996;192:834-9.
22. van Heerden WFP, Van Rensburg EJ, Hemmer J, Raubenheimer EJ, Engelbrecht S. Correlation between p53 gene mutation, p53 gene mutation, p53 protein labeling and PCNA expression in oral squamous cell carcinomas. Anticancer Res 1998;18:237-40.
23. Zhan Q, Bieszczad CK, Bae I, Fornace AJ Jr., Craig RW. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene 1997;14:1031-9.
24. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplaton resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
25. Jonathan J, Herod O, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res 1996;56: 2178-84.